Evidence map›Paper›PMID 41930336›Full record

ReviewMedComm2026

Axon Initial Segment: Structure, Biological Functions, Diseases, and Therapeutic Targets.

Dong-Yan Song, Lin Yuan, Weiguo Yang, Wen Li, Jia-Yi Li

Abstract readReview
In one paragraph

Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dong-Yan SongLaboratory of Research in Parkinson's Disease and Related Disorders Health Sciences Institute Key Laboratory of Major Chronic Diseases of Nervous System of Liaoning Province China Medical University Shenyang China.
Lin YuanLaboratory of Research in Parkinson's Disease and Related Disorders Health Sciences Institute Key Laboratory of Major Chronic Diseases of Nervous System of Liaoning Province China Medical University Shenyang China.
Weiguo YangDepartment of Neurobiology Key Laboratory of Cell Biology Ministry of Public Health and Key Laboratory of Medical Cell Biology Ministry of Education China Medical University Shenyang China.
Wen LiLaboratory of Research in Parkinson's Disease and Related Disorders Health Sciences Institute Key Laboratory of Major Chronic Diseases of Nervous System of Liaoning Province China Medical University Shenyang China.
Jia-Yi LiLaboratory of Research in Parkinson's Disease and Related Disorders Health Sciences Institute Key Laboratory of Major Chronic Diseases of Nervous System of Liaoning Province China Medical University Shenyang China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The axon initial segment (AIS) is a specialized neuronal microdomain that serves as a physical diffusion barrier, separating the axon from somatodendritic compartments. As a highly plastic structure, the AIS dynamically regulates neuronal excitability and contributes to circuit homeostasis. Recent advances in super-resolution imaging and disease modeling have expanded our understanding of its role in neurodevelopment and neurodegenerative disorders. This review first systematically outlines the molecular architecture of the AIS, including its cytoskeletal scaffolds and ion-channel complexes. Then, we discuss AIS plasticity, ranging from activity-dependent alterations to the molecular mechanisms that regulate it, and to its key biological functions, such as its role in action potential initiation, neuronal polarization, subcellular organelle sorting, and neural circuit excitability. We further highlight emerging evidence that AIS disruption represents an early pathological event in neurodegenerative and neuropsychiatric disorders. By integrating physiological and pathological perspectives, and by evaluating emerging biomarker strategies and therapeutic interventions, this review outlines directions and challenges for future AIS-targeted therapies. Meanwhile, it summarizes key experimental and potential clinical tools for future AIS research. Overall, elucidating the molecular mechanism of the AIS in both health and disease provides a deeper understanding for advancing the diagnosis and treatment of neurological diseases.

Indexed as

action potentialaxon initial segmentneural circuitneurological disordersplasticity

Identifiers

PMID41930336
PMCPMC13042750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.